Table 2.
Representative viral miRNA delivery vectors for regenerative medicine
| Viral vectors | Target miRNA | Cell type | Therapeutic approaches | MiRNA level variation | Potential application | Ref. |
|---|---|---|---|---|---|---|
| Adenovirus | MiR-375 | Alveolar epithelial cell | Replacement | ~17 fold increase | Lung recovery | [135] |
| Adeno-assoc iated virus | MiR-26a | Myoblast | Inhibition | About 75% knockdown | Myogenesis | [73] |
| Retrovirus | MiR-138 | MEFs | Replacement | >1000 fold increase | Cellular reprogramming | [123] |
| Retrovirus | MiR-205 | Hair follicle stem cells | Inhibition | Nearly 100% knockdown | Skin recovery | [136] |
| Retrovirus | MiR-106b; miR-93; miR-25 | NSPCs | Replacement | miR-106b: ~18 fold; miR-93: ~15 fold; miR-25: ~30 fold | Neurogenesis | [125] |
| Lentivirus | MiR-424 | hDPCs | Inhibition | 70% knock down | Osteogenesis | [128] |
| Lentivirus | MiR-31 | Bone marrow stromal stem cells | Inhibition | ~90% knock down | Osteogenesis | [51] |
| Lentivirus | MiR-346 | hBMSCs | Replacement | 5.5 fold increase | Osteogenesis | [137] |
| Lentivirus | MiR-153; miR-181a/a*; miR-324-5p/3p | Human neural stem cell | Replacement | 10~300 fold increase | Neurogenesis | [138] |
| Lentivirus | MiR-1 | MSCs | Replacement | ~300 fold increase | Cardiogenesis | [129] |
| Lentivirus | MiR-143; miR-145 | Corneal epithelial progenitor cells | Replacement | MiR-143: 2487 fold increase; miR-145: 876 fold increase | Vasculogenesis | [139] |
| Baculovirus | MiR-26a; miR-29b; miR-148b;miR-196a | hASCs | Replacement | miR-26a: ~5 fold; miR-29b: ~5 fold; miR-148b: ~8 fold increase; miR-196a: ~3 fold increase | Osteogenesis | [134] |